MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Synucleinopathies"

  • 2018 International Congress

    A founder French-Canadian GBA mutation, p.W378G, as a cause for synucleinopathies and Gaucher disease

    Z. Gan-Or, J. Ruskey, S. Zhou, L. Roncière, A. Alam, D. Spiegelman, J. Trempe, R. Postuma, N. Dupre, D. Amato (Montreal, QC, Canada)

    Objective: To examine and characterize founder GBA mutations in the French-Canadian (FC) population Background: GBA mutations are the most common genetic risk factors for Parkinson’s…
  • 2018 International Congress

    Temporal evolution of biomarkers from healthy ageing, isolated REM sleep behavior to early Parkinson’s disease

    B. Mollenhauer, M-L. Muntean, J. Zimmermann, K. Focke, T. Wicke, J. Ebentheuer, M. Schaumburg, E. Lang, WH. Oertel, F. Sixel-Döring, C. Trenkwalder (Kassel, Germany)

    Objective: To study the temporal evolution of biomarkers of various modalities in healthy ageing controls (HC), the prodromal condition of isolated REM sleep behavior disorder…
  • 2018 International Congress

    GBA haploinsufficiency accelerated alpha synuclein pathology with altered lipid metabolism in a premotor model of Parkinson’s disease

    H. Yamakado, M. Ikuno, H. Akiyama, L. Parajuli, K. Taguchi, J. Hara, N. Uemura, Y. Hatanaka, K. Higaki, M. Tanaka, M. Koike, Y. Hirabayashi, R. Takahashi (Kyoto, Japan)

    Objective: To make Parkinson’s disease (PD) mice model and investigate the mechanism how glucocerebrosidase (gba) heterozygous mutations contribute to asyn pathology and development of PD.…
  • 2018 International Congress

    Natural occurring antibodies reduce aggregation of α-synuclein

    A. Braczynski, E. Agerschou, Y. Kronimus, W. Hoyer, R. Dodel, B. Falkenburger, J. Schulz, J. Bach (Aachen, Germany)

    Objective: We tested naturally occurring antibodies (nAbs) against α-synuclein both in vitro as well as in HEK293T cells to determine binding, cell viability and capacity…
  • 2017 International Congress

    Results From a Phase 1b Multiple Ascending-Dose Study of PRX002, an Anti–Alpha-Synuclein Monoclonal Antibody, in Patients with Parkinson’s Disease

    J. Jankovic, I. Goodman, B. Safirstein, D. Schenk, G. Kinney, M. Koller, D. Ness, S. Griffith, M. Grundman, J. Soto, S. Ostrowitzki, F. Boess, M. Martin-Facklam, J. Quinn, S. Isaacson, D. Jennings, O. Omidvar, A. Ellenbogen (Houston, TX, USA)

    Objective: To evaluate PRX002 in patients with PD in a double-blind, placebo-controlled, phase 1b multiple ascending-dose study. Background: PRX002 (RG7935) is an investigational monoclonal antibody…
  • 2017 International Congress

    The novel Parkinson´s disease locus RIT2 and alpha-synuclein function in intersecting pathways

    M. Volta, J. Obergasteiger, C. Überbacher, C. Ascione, C. Corti, A. Hicks, P. Pramstaller (Bolzano, Italy)

    Objective: We aim to describe the molecular pathways at the crossroad of etiology and susceptibility in PD, focusing on Rin, coded by the recently associated…
  • 2017 International Congress

    Brain insulin resistance in Parkinson’s disease

    F. Bassil, M.-H. Canron, N. Dutheil, A. Vital, E. Bezard, P.-O. Fernagut, W. Meissner (Bordeaux, France)

    Objective: To test the hypothesis that brain insulin resistance (i.e. decreased insulin/insulin like growth factor (IGF)-1 signaling) occurs in the substantia nigra pars compacta (SNc)…
  • 2017 International Congress

    Normal “heart” in Parkinson’s disease: Is this a distinct clinical phenotype?

    J.E. Lee, J.-S. Kim, Y.-S. Oh, D.-W. Ryu, I.-U. Song, K.-S. Lee (Seoul, Republic of Korea)

    Objective: The aim of this study was to investigate whether non-motor manifestations of Parkinson’s disease (PD) differ between patients with normal and abnormal myocardial metaiodobenzylguanidine (MIBG)…
  • 2017 International Congress

    Alpha-synuclein enhances histone H3 lysine-9 dimethylation

    N. Sugeno, S. Jäckel, A. Voigt, T. Hasegawa, P. Kahle (Tübingen, Germany)

    Objective: To explore the nuclear function of alpha-synuclein (αS). Background: αS is a protein linked to Parkinson’s disease (PD) and related neurodegenerative disorders. It is…
  • 2017 International Congress

    Extracellular alpha-synuclein internalizes into cells by hijacking endocytic trafficking of dopamine transporter

    J. Kobayashi, T. Hasegawa, N. Sugeno, S. Yoshida, A. Kikuchi, A. Takeda, M. Aoki (Sendai, Japan)

    Objective:  The main purposes of this study were to: 1) investigate the possible effect of extracellular alpha-synuclein (aSYN) on the endocytic rate of dopamine transporter…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 17
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #29077 (not found)
  • #29056 (not found)
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • #28189 (not found)
  • Welcome to the MDS Abstracts Site
  • Advanced Search
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley